Analyst Price Target is $13.00
▲ +240.31% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $13.00, with a high forecast of $14.00 and a low forecast of $12.00. The average price target represents a 240.31% upside from the last price of $3.82.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Capricor Therapeutics.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.